Alnylam Pharmaceuticals has granted Calando Pharmaceuticals an InterfeRx license to discover, develop, and commercialize an RNAi therapeutic towards a cancer target utilizing a synthetic siRNA, together with Calando’s proprietary delivery technology. As part of the agreement, Calando also has an option to acquire an InterfeRx license for a second target gene. Financial terms were not disclosed, but include upfront, annual, and milestone payments, and royalties on sales of any products cove...